Puma Biotechnology"s Licensing Partner Specialised Therapeutics Asia Receives Regulatory Approval to Commercialize NERLYNX (neratinib) for Extended Adjuvant Treatment...
LOS ANGELES--(BUSINESS WIRE)--Mar 18, 2019--Puma Biotechnology, Inc. (Nasdaq: PBYI) announced that its licensing partner Specialised Therapeutics Asia (STA) has received marketing…
